Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of Epoetin Alfa for Initiation and Maintenance Treatment of Patients With Anemia Associated With Chronic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Meet the diagnostic criteria for chronic kidney disease, defined as a glomerular filtration rate (GFR) more than or equal to 15 mL/min per 1.73 m2 and less than 60 mL/min per 1.73 m2 (Stages 3 and 4) as calculated by the central laboratory~* Require support of an erythropoietin receptor agonist~Exclusion Criteria:~* Uncontrolled hypertension~* Serum ferritin level less than 50 ng/mL~* Serum iron overload~* Severe congestive heart failure~* Active infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TIW: Epoetin alfa 3 injections Weekly/Once Weekly (Type: EXPERIMENTAL): Participants will be administered with epoetin alfa 3 times weekly for 22 weeks (initial subcutaneous (SC) dose 50 IU/kg), then once weekly, for 22 weeks (initial SC dose 10,000 IU)
- QW: Epoetin alfa once weekly (Type: EXPERIMENTAL): Participants will be administered with epoetin alfa once weekly for 44 weeks (initial subcutaneous dose 10,000 IU).
- Q2W: Epoetin alfa once every two weeks (Type: EXPERIMENTAL): Participants will be administered with epoetin alfa once every 2 weeks for 44 weeks (initial subcutaneous dose 20,000 IU).

Based on this trial design, predict the completion outcome and termination type (if applicable).